Seung-Whan Lee, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Guidewire Updates: Concept and Technology
  2. Korea CTO Strategy of ADR
  3. Summary of CTO Technique for Beginners: We Can Do It.
  4. When and How to Change Your Plan A to Plan B
  5. The Contribution of Retrograde Approach in CTO PCI
  6. DECISION-CTO Trial: Updated QOL and Outcome Data
  7. Antegrade Approach in Korea 2018
  8. Expert Case Presentation: My Challenging CTO PCI
  9. DECISION-CTO Trial: Treat or Not Treat CTO
  10. LUTONIX Korean Registry Data
  11. The Lesson from DECISION-CTO Trial
  12. Carotid Artery Stenting; Indication & Technical Issue
  13. Comparable Impact of OMT After Failed Versus Successful CTO-PCI
  14. Class Effect of DCB?
  15. CTO-PCI: Simple Approach Has Evidence
  16. Full-Metal Jacket in CTO-PCI from AMC Registry: Safe or Not?
  17. How to Manage Complex SFA Lesions
  18. Should We Open Every CTO?: DECISION CTO
  19. IN PACT SFA Randomized Trial: DCB Becomes First Line Therapy
  20. TAVI for Patients with Peripheral Artery Disease
  21. Against: Don\'t Care of CTO Expertise
  22. Angiosome-based Intervention Is Associated with Improved Outcomes
  23. Medical Treatment of Symptomatic PAD: The Role of Cilostazol
  24. CTO: See the Unseen - Function Rather than Anatomy
  25. Clinical Data Update for DEB
  26. Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-V: Biolimus A9-Eluting (NOBORI) vs. Everolimus-eluting (PROMUS-ELEMENT) Stent: LONG V Trial Preliminary Data
  27. Asymptomatic Carotid Artery Stenosis: Is Really Risky? Must Be Recanalized?
  28. Cooler: Not Over till Over, PCI Is Getting Better!
  29. CTO-PCI: Success or Failure Doesn\'t Matter: From Asan CTO Registry
  30. BTK Intervention
  31. Triple Antiplatelet Therapy in DES Era: Default Strategy in High Risk Population
  32. Fielder XT: Initial and Professional Use for CTO
  33. Tailored Approach to Reduction of Restenosis after DES Implantation: Results from Pooled Analysis of DECLARE Trials
  34. Comparison of Sirolimus-eluting vs. Everolimus-eluting Stents in Diabetic and Non-Diabetic Patients: Results from the IRIS-DES Registry and the ESSENCE-DIABETES Clinical Trial
  35. Take Home Message with Special Lecture
  36. How & Why CTO?_Passion, Confidence, Success and Happiness
  37. Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel?